Our translational research focuses on oncolytic measles viruses for cancer therapy. A Phase I/II clinical trial of immunovirotherapy for metastatic pancreatic cancer is currently in preparation.
- Development of oncolytic Measles virus vectors encoding anti-CTLA-4 and anti-PD-L1 to enhance immunovirotherapy and reduce side effects of checkpoint blockade (Engeland et al., Molecular Therapy 2014)
- Proof of concept that oncolytic Measles virus can induce tumor-specific immunity, resulting in a protective tumor vaccination effect (Grossardt et al., Human Gene Therapy 2013)
- Post-entry targeting of measles virus vectors via insertion of microRNA to increase safety of oncolytic agents (Leber et al. Molecular Therapy 2011; Baertsch et al., Cancer Gene Therapy 2014)
- Establishment of targeted chemovirotherapy against lymphoma (Ungerechts et al. Cancer Research 2007; Ungerechts et al. Gene Therapy 2010), pancreatic cancer (Bossow et al. Cancer Gene Therapy 2011), head and neck cancer (Zaoui et al. Gene Therapy 2011) and malignant melanoma (Kaufmann et al. J Invest Dermatol 2013)